Caribou Biosciences stock closed Tuesday with a bearish daily structure, despite oversold readings across all three timeframes. The session ended at $1.14, below its daily exponential averages and at the lower Bollinger band. Oversold conditions complicate the bearish case but do not establish a reversal.
Key takeaways
- CRBU closed Tuesday at $1.14, a decline of 4.62%, on volume of 4,642,000 shares.
- Daily RSI14 is 27.68, in oversold territory, after reading 31.29 on October 5.
- Price sits below the 20-session EMA at $1.29, the 50-session EMA at $1.44, and the 200-session EMA at $1.70.
- The daily lower Bollinger band is $1.14, matching the session close. Hourly RSI14 is 26.44 and 15-minute RSI14 is 23.85 — both in oversold territory.
- The daily pivot for the next session is $1.16, with first resistance at $1.19 and first support at $1.10.
On Tuesday, October 6, 2026, CRBU opened at $1.19, traded between a low of $1.13 and a high of $1.22, and closed at $1.14. The session change was -4.62% versus the previous close, with volume of 4,642,000 shares. Prices and technical indicators are from Twelve Data.
Caribou Biosciences Stock Remains Below Its Daily Averages
The daily averages are bearishly aligned. That ordering supports the bearish main scenario. A bullish case needs more than an oversold reading; it needs price to reclaim overhead levels.
However, daily RSI14 fell to 27.68 from 31.29 on October 5, placing it in oversold territory. The daily MACD line and signal both stand at -0.09, while the histogram is 0. The negative line supports the bearish bias, but the zero histogram provides no separation from the signal at the reported precision.
Meanwhile, the daily Bollinger lower band is $1.14, matching the session close. The mid-band at $1.27 and upper band at $1.40 sit above price. Daily ATR14 reads $0.06, providing a volatility reference without establishing direction.
Hourly Confirmation With Oversold Execution Conditions
The hourly chart confirms the daily bias for CRBU. The session close sits below the 20-hour EMA at $1.19, the 50-hour EMA at $1.22, and the 200-hour EMA at $1.36. These averages are also bearishly aligned. Hourly RSI14 is 26.44, in oversold territory, while the MACD histogram is -0.01, a negative momentum reading.
At the same time, the session close sits above the hourly lower Bollinger band at $1.13 but below its mid-band at $1.19. The upper band is $1.25, and hourly ATR14 is $0.02. There is no bullish timeframe disagreement here; the tension is between bearish positioning and oversold RSI readings.
15-Minute Execution Context
For execution context, the 15-minute RSI14 is 23.85, also oversold. Price sits below the 20-quarter-hour EMA at $1.16, the 50-quarter-hour EMA at $1.18, and the 200-quarter-hour EMA at $1.23. The 15-minute MACD histogram is 0, offering no positive momentum confirmation. Its lower Bollinger band is $1.12, its mid-band is $1.16, and its upper band is $1.20; ATR14 is $0.01.
News Published After the Session
Separately, a Yahoo Finance report published after Tuesday’s close said Caribou plans to evaluate strategic alternatives. It also said the company plans to discontinue its vispa-cel and CB-011 allogeneic CAR-T cell therapy programs. An Investing.com report published after the same close described strategic alternatives and a halt to CAR-T programs.
Subsequently, an Investing.com report published on Wednesday, October 7, said RBC Capital cut its rating on Caribou Biosciences stock on a strategic review. That report belongs to the following day, not Tuesday’s session.
Bullish and Bearish Conditions for the Next Session
The daily pivot for the next session sits at $1.16, with first resistance at $1.19 and first support at $1.10. These levels are derived from the last completed daily candle and apply when trading resumes.
A bullish scenario would require price to hold above the session low at $1.13 and reclaim the daily pivot at $1.16. Clearing daily first resistance at $1.19 would strengthen that case. The next daily reference points are the Bollinger mid-band at $1.27 and the 20-session EMA at $1.29. An RSI14 reading above 30 would remove the daily oversold designation, though not establish a bullish trend.
In contrast, a break below the session low at $1.13 would undermine that bullish case. A further break below daily first support at $1.10 would reinforce the bearish scenario. Remaining below the daily pivot at $1.16 would leave the nearest overhead barrier unresolved.
Overall, CRBU’s $1.14 close sits at the daily lower Bollinger band and below all three daily averages. Daily ATR14 is $0.06, while the hourly and 15-minute readings are $0.02 and $0.01. The bearish structure is clear; whether oversold conditions translate into reclaimed resistance remains uncertain.
FAQ
What is the technical structure of Caribou Biosciences stock?
CRBU closed Tuesday at $1.14, below its 20-session EMA at $1.29, 50-session EMA at $1.44, and 200-session EMA at $1.70. The daily RSI14 is 27.68, in oversold territory, and the daily MACD histogram is 0.
What are the key levels to watch for CRBU?
The daily pivot for the next session is $1.16. First resistance sits at $1.19 and first support at $1.10. The daily lower Bollinger band at $1.14 matched Tuesday’s close. Above that, the Bollinger mid-band at $1.27 and the 20-session EMA at $1.29 are the next overhead reference points.
What news was published after the close regarding Caribou Biosciences?
A Yahoo Finance report published after Tuesday’s close said the company plans to evaluate strategic alternatives and discontinue its vispa-cel and CB-011 allogeneic CAR-T cell therapy programs. An Investing.com report published on Wednesday, October 7, said RBC Capital cut its rating on Caribou Biosciences stock on a strategic review.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, an investment recommendation, or a solicitation to buy or sell any financial instrument. The analysis provided is not indicative of future results. Investing in financial markets carries a high risk of capital loss. Always do your own research (DYOR) and consult a qualified financial advisor before making any decision.
Cryptonomist and the author hold no positions in the financial instruments mentioned and receive no compensation from the companies covered.
Article produced with the assistance of artificial intelligence and reviewed by the editorial team.